MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Apellis Pharmaceuticals Operating Cash Flow 2011-2026 | APLS
Annual Operating Cash Flow Apellis Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 45.3 M | -87.9 M | -595 M | -514 M | -563 M | -160 M | -211 M | -131 M | -46.6 M | -26 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 45.3 M | -595 M | -229 M |
Quarterly Operating Cash Flow Apellis Pharmaceuticals
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -53.4 M | - | - | - | -133 M | - | - | - | -178 M | - | -373 M | -219 M | -112 M | - | -451 M | -282 M | -153 M | - | -302 M | -203 M | -108 M | - | -129 M | -75.5 M | -35.6 M | - | -86.8 M | -53.6 M | -22.9 M | - | -31.1 M | -19.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -19.9 M | -451 M | -151 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
BioLineRx Ltd.
BLRX
|
-23.6 M | $ 2.25 | 1.81 % | $ 908 M |  Israel |
 |
BioNTech SE
BNTX
|
890 M | $ 91.28 | 0.11 % | $ 27.2 B |  Germany |
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M | Germany |
 |
Alnylam Pharmaceuticals
ALNY
|
524 M | $ 330.34 | 3.6 % | $ 43.3 B |  USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-14.1 M | $ 0.44 | -16.64 % | $ 5.04 M | Israel |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
99.9 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M | France |
 |
Catalyst Pharmaceuticals
CPRX
|
209 M | $ 24.98 | 1.17 % | $ 3.05 B | USA |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
-64.5 M | $ 10.14 | -0.29 % | $ 135 M | USA |
 |
Cardiff Oncology
CRDF
|
-37.9 M | $ 1.58 | - | $ 106 M | USA |
 |
Curis
CRIS
|
-27.2 M | $ 0.53 | -3.07 % | $ 6.98 M | USA |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
-378 M | $ 37.7 | 1.26 % | $ 3.55 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-345 M | $ 49.15 | -0.73 % | $ 4.42 B |  Schweiz |
 |
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
-29.5 M | - | -9.65 % | $ 45.9 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
-39 M | $ 2.96 | -1.0 % | $ 252 M | USA |
 |
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-18 M | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
22.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
CytomX Therapeutics
CTMX
|
-75.6 M | $ 4.4 | -3.51 % | $ 607 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-65.7 M | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
-230 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-63.7 M | - | 0.23 % | $ 488 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
-28.2 M | $ 0.86 | 0.67 % | $ 5.79 M | USA |
 |
Cue Biopharma
CUE
|
-21.7 M | $ 0.18 | -1.61 % | $ 17.1 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-45.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-19.4 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aquestive Therapeutics
AQST
|
-52.4 M | $ 4.09 | -0.97 % | $ 437 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
-4.33 M | $ 4.15 | -32.52 % | $ 10.4 M | USA |
 |
Daré Bioscience
DARE
|
-9.89 M | $ 1.81 | 4.02 % | $ 20.2 M | USA |
 |
DBV Technologies S.A.
DBVT
|
-121 M | $ 20.36 | -3.32 % | $ 2.84 B | France |
 |
Aravive
ARAV
|
-65.1 M | - | -13.39 % | $ 1.45 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-74.3 M | $ 8.22 | 2.37 % | $ 225 M | Israel |
 |
Aptose Biosciences
APTO
|
-22 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-59.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Denali Therapeutics
DNLI
|
-348 M | $ 19.38 | -6.15 % | $ 3.19 B | USA |
 |
Dyadic International
DYAI
|
-5.7 M | $ 0.87 | -2.8 % | $ 31.5 M | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
AstraZeneca PLC
AZN
|
5.96 B | - | - | $ 96.9 B | Britain |
 |
Celldex Therapeutics
CLDX
|
-211 M | $ 31.37 | 1.0 % | $ 2.08 B | USA |
 |
Avenue Therapeutics
ATXI
|
-1.83 M | - | -52.27 % | $ 4.45 M | USA |